Ropes Wealth Advisors’s NovoCure NVCR Stock Holding History

Ropes Wealth Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-236	Closed	-$41K	–	602
2020 Q4	$41K	Hold	236	–	–	0.01%	409
2020 Q3	$26K	Hold	236	–	–	0.01%	402
2020 Q2	$14K	Hold	236	–	–	﹤0.01%	427
2020 Q1	$16K	Hold	236	–	–	﹤0.01%	383
2019 Q4	$20K	Hold	236	–	–	﹤0.01%	416
2019 Q3	$18K	Buy	+236	New	+$18.9K	﹤0.01%	446

Other funds holding NVCR

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ropes Wealth Advisors's NVCR Position: Q1 2021 in Review

Ropes Wealth Advisors sold out of NovoCure (NVCR) in Q1 2021, closing a stake of 236 shares — an estimated $41K sold.

Ropes Wealth Advisors first reported a position in NVCR in Q3 2019 and held it in 6 quarters. The position peaked at $41K in Q4 2020. 327 funds tracked by Wall St. Rank hold NVCR as of Q1 2021.

Ropes Wealth Advisors reported no remaining NovoCure position as of Q1 2021 after selling out during the quarter.
Ropes Wealth Advisors sold 236 NovoCure shares in Q1 2021, an estimated $41K.
Ropes Wealth Advisors first reported a position in NovoCure in Q3 2019 and held it in 6 quarters.
Ropes Wealth Advisors's NovoCure position peaked at $41K in Q4 2020.
327 funds tracked by Wall St. Rank held NovoCure as of Q1 2021.

Based on Ropes Wealth Advisors's 13F filing for Q1 2021, filed 12 May 2021.